7/25/2013

Cognitive ability of clinical trial participants with mild to moderate Alzheimer's disease declined faster in the group taking gamma secretase-blocker semagacestat than in the placebo group, researchers report in The New England Journal of Medicine. The drug, designed to block an enzyme that makes beta amyloid plaques in the brain, worked as designed in early human and animal trials but failed to improve thinking skills in this trial.

Full Story:
HealthDay News

Related Summaries